

Editorial Board of Trend in Bio/Pharmaceutical Industry

Editor in Chief

Wang, Jianxin *Novartis, USA*

Board of Scientific Editors

An, Songzhu *Amgen, USA*

Han, Jun *Barr, USA*

Li, Bin *Abbot, China*

Li, Hui *Pfizer, USA*

Liu, Chuan *Medidata, USA*

Mo, Chengjun *Medimmune, USA*

Shi, Li *Genzyme, USA*

Wang, Deqian *Bayer, China*

Wang, Yanni *Int. Biomed Communication*

Wei, Yingfei *3Sbio, China*

Yang, Dajun *Morningstar, USA*

Yang, Pei *Portola, USA*

Yang, Naibo *Biochain, USA*

Zhang, Philip *Cooley Godward Kronish, USA*

Managing Editor

Xiang, Jun *Bayer, USA*

Art Editor

Li, Xiaojun *CA State, USA*

Pages Design

Sun, Wei *Today Design*

Legal Counsel

Huang, Tao *Morgan Lewis, USA*

Published by

The Alliance of Chinese American Biotechnology and Pharmaceutical Associations
(*中华药盟*, www.all-cabpa.org)

Partners in Publication

Chinese Pharmaceutical Journal, China
Progress in Pharmaceutical Science, China

Partner in Commerce

Simcere, China

Contact Us

TBI online: www.tbiweb.org

Email: editor@tbiweb.org
info@tbiweb.org

Letter from Editor



Dear friends and colleagues,

It is my great pleasure to introduce this new issue of TBI, our first issue dedicated to the topic of intellectual property.

As TBI evolves from a local scientific publication towards a mainstream industrial journal in the Chinese-American biotech/pharmaceutical community, it is embraced with a significant expansion of readership with increased sophistication. To continue to meet the growing needs of our readers and provide in-depth analyses in particular areas of interests, we have published several issues dedicated to specific topics, such as personalized medicine, stem cell research, and avian flu. The present issue reflects our continued efforts in serving the interests of our readers.

Intellectual property (IP) is the driving force behind innovation, and provides incentive for long-term investment. It plays pivotal roles in the biotech/pharmaceutical industry, which relies heavily on innovation and long-term investment. Whether you are a scientific researcher or an emerging entrepreneur, a general understanding of IP issues will give you significant competitive advantage in building a successful career in the biotech/pharmaceutical industry. Over the years, we have introduced various topics on the evolving IP law to our readers. To provide our readers with an opportunity to better understand the intricacies and practical considerations of intellectual property law, we have dedicated this issue of TBI to the topic of intellectual property.

The articles included in this issue focus on IP issues in different facets of the biotech/pharmaceutical industry. Some of the issues are of imminent importance. For example, use of stem cells in drug discovery and clinical treatment has emerged at the forefront of the biopharmaceutical industry. Understanding IP issues related to stem cell research and application is critical for those planning to delve into this area. For this purpose, we have invited Drs. Terri Shieh-Newton and Catherine Polizzi to discuss IP considerations surrounding stem cells and regenerative medicine, including obtaining patent protection, ensuring freedom to operate, and other legal considerations unique to stem cell research. Equally important is the article by Dr. Cynthia Zhang discussing legal issues at the crossroad of IP law and the FDA drug regulation, with a particular emphasis on the interplay between patent delisting and the 180-day market exclusivity for innovative drug developers.

For those who are planning to launch a biopharmaceutical enterprise in China, we have further included three original articles with a special focus on IP considerations in China. This series of articles begin with a policy discussion by me and my colleague Kun Wang on China's IP environment. This is followed by an article by Dr. Philip Zhang, who provides an overview of IP strategies for Chinese biotech and pharmaceutical companies from a practical perspective. Finally, an article authored by Thomas Duley provides an in-depth analysis of key principles for building successful biotechnology licenses and collaborations between Chinese and Western companies.

I would like to thank our authors for their valuable time and candidness in dissecting some of the most complex IP issues for our readers. I would also like to thank members of the Chinese/American Intellectual Property Law Association (CIPLA), including Drs. Philip Zhang and Tao Huang, who are instrumental in putting this special issue together.

I hope you find this special issue resourceful and informative, and we welcome your valuable comments and feedback. Enjoy!

Janet Xiao, PhD and JD
Morrison & Foerster LLP